New York, NY– March 1.  The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human DNA sequences.

The study will be offered in 20 research centers throughout the country, many of which are part of the  Lupus Clinical Investigators Network (LuCIN) that Lupus Therapeutics oversees.

The full press release is available on the Lupus Therapeutics website.

Read full Press Release